Portal hypertension secondary to myelofibrosis with myeloid metaplasia: A study of 13 cases

World Journal of Gastroenterology

Volumn 15, Issue 25, 2009, Pages 3128-3133

  Abu Hilal, Mohannad ^a   Tawaker, Jayant ^a  

^a Mayo Clinic   (United States)

Author keywords

Ascites; Myelofibrosis; Myeloid metaplasia; Portal hypertension; Variceal bleeding

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN;

ABDOMINAL PAIN; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; DISEASE SEVERITY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LEUKOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MALE; MELENA; MYELOID METAPLASIA; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; SPLENOMEGALY; VEIN LIGATION;

EID: 67651247376     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.3128     Document Type: Article

References (43)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255-1265
2. Shaldon S, Sherlock S. Portal hypertension in the myeloproliferative syndrome and the reticuloses. Am J Med 1962; 32: 758-764
3. Mesa RA, Barosi G, Cervantes F, Reilly JT, Tefferi A. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. Best Pract Res Clin Haematol 2006; 19: 495-517
4. Sullivan A, Rheinlander H, Weintraub LR. Esophageal varices in agnogenic myeloid metaplasia: disappearance after splenectomy. A case report. Gastroenterology 1974; 66: 429-432
5. Dagradi AE, Siemsen J, Brook J, Stempien SJ. Bleeding esophageal varices in myelofibrosis. Am J Gastroenterol 1965; 44: 536-544
6. Roux D, Merlio JP, Quinton A, Lamouliatte H, Balabaud C, Bioulac-Sage P. Agnogenic myeloid metaplasia, portal hypertension, and sinusoidal abnormalities. Gastroenterology 1987; 92: 1067-1072
7. Takasaki M, Takahashi I, Takamatsu M, Yorimitsu S, Yorimitsu Y, Takeda I, Horimi T. Endoscopic injection sclerotherapy for esophageal variceal hemorrhage in a patient with idiopathic myelofibrosis. J Gastroenterol 1996; 31: 260-262
8. Silverstein MN, Wollaeger EE, Baggenstoss AH. Gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia. Arch Intern Med 1973; 131: 532-537
9. Ligumski M, Polliack A, Benbassat J. Nature and incidence of liver involvement in agnogenic myeloid metaplasia. Scand J Haematol 1978; 21: 81-93
10. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 1997; 80: 708-719
11. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-1018
12. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe Spiriti MA, Latagliata R. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990; 75: 4-9
13. Thiele J, Steinberg T, Zankovich R, Fischer R. Primary myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia): correlation of clinical findings with bone marrow histopathology and prognosis. Anticancer Res 1989; 9: 429-435
14. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 1988; 70: 397-401
15. Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684-690
16. Dubois A, Dauzat M, Pignodel C, Pomier-Layrargues G, Marty-Double C, Lopez FM, Janbon C. Portal hypertension in lymphoproliferative and myeloproliferative disorders: hemodynamic and histological correlations. Hepatology 1993; 17: 246-250
17. Lee WC, Lin HC, Tsay SH, Yang YY, Hou MC, Lee FY, Chang FY, Lee SD. Esophageal variceal ligation for esophageal variceal hemorrhage in a patient with portal and primary pulmonary hypertension complicating myelofibrosis. Dig Dis Sci 2001; 46: 915-919
18. Escartín Marin P, Arenas Mirave JI, Boixeda D, Hernández Ranz F, García Plaza A. [Hemodynamic study of the portal system in 6 cases of myeloid metaplasia] Rev Clin Esp 1977; 145: 271-273
19. Wanless IR, Peterson P, Das A, Boitnott JK, Moore GW, Bernier V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology 1990; 12: 1166-1174
20. Blendis LM, Banks DC, Ramboer C, Williams R. Spleen blood flow and splanchnic haemodynamics in blood dyscrasia and other splenomegalies. Clin Sci 1970; 38: 73-84
21. Rosenbaum DL, Murphy GW, Swisher SN. Hemodynamic studies of the portal circulation in myeloid metaplasia. Am J Med 1966; 41: 360-368
22. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985; 248: G618-G625
23. Petz LD. Hematologic aspects of liver disease. Curr Opin Gastroenterol 1989; 5: 372-377
24. Pizcueta P, Piqué JM, Fernández M, Bosch J, Rodés J, Whittle BJ, Moncada S. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 1909-1915
25. Pizcueta MP, Piqué JM, Bosch J, Whittle BJ, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992; 105: 184-190
26. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992; 103: 235-239
27. Lee WC, Lin HC, Hou MC, Lee FY, Chang FY, Tsai YT, Lee SD. Effect of anaemia on haemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 1999; 14: 370-375
28. Cirera I, Elizalde JI, Piqué JM, Feu F, Casadevall M, Goldin E, Terés J, Bosch J, Rodés J. Anemia worsens hyperdynamic circulation of patients with cirrhosis and portal hypertension. Dig Dis Sci 1997; 42: 1697-1702
29. Hua R, Cao H, Wu ZY. Effects of hemoglobin concentration on hyperdynamic circulation associated with portal hypertension. Hepatobiliary Pancreat Dis Int 2006; 5: 215-218
30. Casadevall M, Piqué JM, Cirera I, Goldin E, Elizalde I, Panés J, Martínez-Cuesta MA, Bosch J, Terés J, Rodés J. Increased blood hemoglobin attenuates splanchnic vasodilation in portal-hypertensive rats by nitric oxide inactivation. Gastroenterology 1996; 110: 1156-1165
31. Lukie BE, Card RT. Portal hypertension complicating myelofibrosis: reversal following splenectomy. Can Med Assoc J 1977; 117: 771-772
32. López-Guillermo A, Cervantes F, Bruguera M, Pereira A, Feliu E, Rozman C. Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematol 1991; 85: 184-188
33. Barosi G, Ambrosetti A, Buratti A, Finelli C, Liberato NL, Quaglini S, Ricetti MM, Visani G, Tura S, Ascari E. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 1993; 7: 200-206
34. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226-2233
35. Alvarez-Larrán A, Abraldes JG, Cervantes F, Hernández-Guerra M, Vizzutti F, Miquel R, Gilabert R, Giusti M, Garcia-Pagan JC, Bosch J. Portal hypertension secondary to myelofibrosis: a study of three cases. Am J Gastroenterol 2005; 100: 2355-2358
36. Perelló A, García-Pagán JC, Gilabert R, Suárez Y, Moitinho E, Cervantes F, Reverter JC, Escorsell A, Bosch J, Rodés J. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002; 35: 132-139
37. Wiest R, Strauch U, Wagner H, Strotzer M, Woenckhaus M, Schröder G, Schölmerich J, Lock G. A patient with myelofibrosis complicated by refractory ascites and portal hypertension: to tips or not to tips? A case report with discussion of the mechanism of ascites formation. Scand J Gastroenterol 2004; 39: 389-394
38. Bělohlávek J, Schwarz J, Jirásek A, Krajina A, Polák F, Hrubý M. Idiopathic myelofibrosis complicated by portal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS). Wien Klin Wochenschr 2001; 113: 208-211
39. Tanaka N, Yamakado K, Kihira H, Hashimoto A, Murayama T, Takeda K. Re: Transjugular intrahepatic portosystemic shunt for intractable esophageal-gastric variceal hemorrhage in a patient with idiopathic myelofibrosis. Cardiovasc Intervent Radiol 2000; 23: 491-492
40. Goh BK, Chen JJ, Tan HK, Yong WS, Chan WH. Acute variceal bleed in a patient with idiopathic myelofibrosis successfully treated with endoscopic variceal band ligation. Dig Dis Sci 2007; 52: 173-175
41. Ghidirim G, Corchmaru I, Mishin I, Danch A, Zastavnitsky G. Endoscopic rubber band ligation for bleeding oesophageal varices in portal hypertension due to idiopathic myelofibrosis. J Gastrointestin Liver Dis 2006; 15: 322
42. Nikolaidis N, Giouleme O, Sileli M, Tziomalos K, Grammatikos N, Garipidou V, Eugenidis N. Endoscopic variceal ligation for portal hypertension due to myelofibrosis with myeloid metaplasia. Eur J Haematol 2004; 72: 379-380
43. Hou MC, Lin HC, Kuo BI, Chen CH, Lee FY, Lee SD. Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: a prospective randomized trial. Hepatology 1995; 21: 1517-1522